FUNI Quote, Financials, Valuation and Earnings

Interpace Biosciences, Inc. has a net margin of -- compared to Hypha Labs, Inc.'s net margin of 11.55%. Hypha Labs, Inc.'s return on equity of -- beat Interpace Biosciences, Inc.'s return on equity of --.

Hypha Labs, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Interpace Biosciences, Inc. has an analysts' consensus of -- which suggests that it could grow by 516.25%. Given that Interpace Biosciences, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Interpace Biosciences, Inc. is more attractive than Hypha Labs, Inc..

Hypha Labs, Inc. has a beta of 1.235, which suggesting that the stock is 23.534% more volatile than S&P 500. In comparison Interpace Biosciences, Inc. has a beta of 1.170, suggesting its more volatile than the S&P 500 by 16.957%.

Hypha Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Interpace Biosciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypha Labs, Inc. pays -- of its earnings as a dividend. Interpace Biosciences, Inc. pays out -- of its earnings as a dividend.

Hypha Labs, Inc. quarterly revenues are --, which are smaller than Interpace Biosciences, Inc. quarterly revenues of $8.8M. Hypha Labs, Inc.'s net income of -$521.6K is lower than Interpace Biosciences, Inc.'s net income of $1M. Notably, Hypha Labs, Inc.'s price-to-earnings ratio is 4.88x while Interpace Biosciences, Inc.'s PE ratio is 6.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypha Labs, Inc. is 1.16x versus 0.68x for Interpace Biosciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Thermo Fisher Scientific, Inc. has a net margin of -- compared to Hypha Labs, Inc.'s net margin of 16.21%. Hypha Labs, Inc.'s return on equity of -- beat Thermo Fisher Scientific, Inc.'s return on equity of 13.23%.

Hypha Labs, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Thermo Fisher Scientific, Inc. has an analysts' consensus of $666.46 which suggests that it could grow by 29.99%. Given that Thermo Fisher Scientific, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Thermo Fisher Scientific, Inc. is more attractive than Hypha Labs, Inc..

Hypha Labs, Inc. has a beta of 1.235, which suggesting that the stock is 23.534% more volatile than S&P 500. In comparison Thermo Fisher Scientific, Inc. has a beta of 0.962, suggesting its less volatile than the S&P 500 by 3.778%.

Hypha Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Thermo Fisher Scientific, Inc. offers a yield of 0.34% to investors and pays a quarterly dividend of $0.43 per share. Hypha Labs, Inc. pays -- of its earnings as a dividend. Thermo Fisher Scientific, Inc. pays out 9.7% of its earnings as a dividend. Thermo Fisher Scientific, Inc.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Hypha Labs, Inc. quarterly revenues are --, which are smaller than Thermo Fisher Scientific, Inc. quarterly revenues of $12.2B. Hypha Labs, Inc.'s net income of -$521.6K is lower than Thermo Fisher Scientific, Inc.'s net income of $2B. Notably, Hypha Labs, Inc.'s price-to-earnings ratio is 4.88x while Thermo Fisher Scientific, Inc.'s PE ratio is 28.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypha Labs, Inc. is 1.16x versus 4.35x for Thermo Fisher Scientific, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Veracyte, Inc. has a net margin of -- compared to Hypha Labs, Inc.'s net margin of 29.26%. Hypha Labs, Inc.'s return on equity of -- beat Veracyte, Inc.'s return on equity of 5.39%.

Hypha Labs, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand Veracyte, Inc. has an analysts' consensus of $48.60 which suggests that it could grow by 34%. Given that Veracyte, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe Veracyte, Inc. is more attractive than Hypha Labs, Inc..

Hypha Labs, Inc. has a beta of 1.235, which suggesting that the stock is 23.534% more volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.915, suggesting its more volatile than the S&P 500 by 91.504%.

Hypha Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypha Labs, Inc. pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.

Hypha Labs, Inc. quarterly revenues are --, which are smaller than Veracyte, Inc. quarterly revenues of $140.6M. Hypha Labs, Inc.'s net income of -$521.6K is lower than Veracyte, Inc.'s net income of $41.1M. Notably, Hypha Labs, Inc.'s price-to-earnings ratio is 4.88x while Veracyte, Inc.'s PE ratio is 44.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypha Labs, Inc. is 1.16x versus 5.60x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

XWELL, Inc. has a net margin of -- compared to Hypha Labs, Inc.'s net margin of -2.87%. Hypha Labs, Inc.'s return on equity of -- beat XWELL, Inc.'s return on equity of -224.93%.

Hypha Labs, Inc. has a consensus price target of --, signalling downside risk potential of --. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 418.52%. Given that XWELL, Inc. has higher upside potential than Hypha Labs, Inc., analysts believe XWELL, Inc. is more attractive than Hypha Labs, Inc..

Hypha Labs, Inc. has a beta of 1.235, which suggesting that the stock is 23.534% more volatile than S&P 500. In comparison XWELL, Inc. has a beta of 0.866, suggesting its less volatile than the S&P 500 by 13.449%.

Hypha Labs, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Hypha Labs, Inc. pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.

Hypha Labs, Inc. quarterly revenues are --, which are smaller than XWELL, Inc. quarterly revenues of $7.3M. Hypha Labs, Inc.'s net income of -$521.6K is lower than XWELL, Inc.'s net income of -$211K. Notably, Hypha Labs, Inc.'s price-to-earnings ratio is 4.88x while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Hypha Labs, Inc. is 1.16x versus 0.25x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.